Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Her-2 Positive Gastric Cancer”

189 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 189 results

Early research (Phase 1)Active Not RecruitingNCT04511871
What this trial is testing

A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors

Who this might be right for
Solid TumorGastric CancerBreast Cancer+2 more
Shanghai PerHum Therapeutics Co., Ltd. 12
Testing effectiveness (Phase 2)Ended earlyNCT05188209
What this trial is testing

Evaluate the Efficacy and Safety of MRG003 in Patients With Advanced Gastric Cancer.

Who this might be right for
Advanced or Metastatic Gastric CancerAdvanced or Metastatic Gastroesophageal Junction Carcinoma
Lepu Biopharma Co., Ltd. 6
Large-scale testing (Phase 3)Active Not RecruitingNCT05002127
What this trial is testing

Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)

Who this might be right for
Gastric CancerGastroesophageal Junction AdenocarcinomaGastric Adenocarcinoma
ALX Oncology Inc. 127
Large-scale testing (Phase 3)Ended earlyNCT01641939
What this trial is testing

Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer

Who this might be right for
Gastric Cancer
Hoffmann-La Roche 415
Large-scale testing (Phase 3)Active Not RecruitingNCT04704934
What this trial is testing

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

Who this might be right for
Gastric Cancer, AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Daiichi Sankyo 490
Testing effectiveness (Phase 2)UnknownNCT05311189
What this trial is testing

Study of HLX10, Trastuzumab and Chemotherapy in First-line Treatment of HER2-positive Recurrent/Metastatic Gastric Cancer

Who this might be right for
HER2-positive Gastric Cancer
Shanghai Zhongshan Hospital 40
Testing effectiveness (Phase 2)Ended earlyNCT00447226
What this trial is testing

Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy Exists

Who this might be right for
Cancer
GlaxoSmithKline 32
Very early researchUnknownNCT06224738
What this trial is testing

Human HER2-targeted Macrophages Therapy for HER2-positive Advanced Gastric Cancer With Peritoneal Metastases

Who this might be right for
Gastric Cancer
First People's Hospital of Hangzhou 9
Testing effectiveness (Phase 2)Looking for participantsNCT05965479
What this trial is testing

Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal Cancer

Who this might be right for
Gastrooesophageal Cancer
University of Southampton 25
Testing effectiveness (Phase 2)Study completedNCT02954536
What this trial is testing

Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer

Who this might be right for
Esophageal CancerGastric Cancer
Memorial Sloan Kettering Cancer Center 37
Testing effectiveness (Phase 2)Study completedNCT04276493
What this trial is testing

Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab

Who this might be right for
Breast CancerGastric CancerGastroesophageal Junction Cancer
BeiGene 71
Early research (Phase 1)Study completedNCT01602406
What this trial is testing

Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer

Who this might be right for
Advanced HER2-positive Breast Cancer or Gastric Cancer
Novartis Pharmaceuticals 64
Testing effectiveness (Phase 2)Looking for participantsNCT05640830
What this trial is testing

Trastuzumab, Bevacizumab with Paclitaxel for HER2-positive Gastric Cancer in a Second-line Therapy

Who this might be right for
HER2-positive Advanced Gastric Cancer
Kangbuk Samsung Hospital 47
Not applicableStudy completedNCT05892926
What this trial is testing

HER2-positive Locally Advanced/Metastatic Gastric and/or Gastroesophageal Junction (GEJ) Adenocarcinoma in Russia

Who this might be right for
Adenocarcinoma
AstraZeneca 204
Early research (Phase 1)Looking for participantsNCT06500052
What this trial is testing

BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors

Who this might be right for
Esophageal CancerGastric CancerPancreatic Cancer+2 more
Sichuan Baili Pharmaceutical Co., Ltd. 20
Large-scale testing (Phase 3)Ended earlyNCT01450696
What this trial is testing

Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Who this might be right for
Gastric Cancer
Hoffmann-La Roche 296
Early research (Phase 1)Not Yet RecruitingNCT07333820
What this trial is testing

Clinical Study to Evaluate the Safety and Anti-Tumor Activity of AB-201

Who this might be right for
Malignant Neoplasm of Stomach, Unspecified
Yonsei University 18
Testing effectiveness (Phase 2)Active Not RecruitingNCT05586061
What this trial is testing

First-line Treatment with RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer

Who this might be right for
HER2-positive Gastric Cancer
Qilu Hospital of Shandong University 55
Large-scale testing (Phase 3)Active Not RecruitingNCT03653507
What this trial is testing

Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).

Who this might be right for
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or Cancer+1 more
Astellas Pharma Global Development, Inc.
Testing effectiveness (Phase 2)Looking for participantsNCT05150691
What this trial is testing

A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors

Who this might be right for
HER2-positive Advanced Solid Tumor
DualityBio Inc. 796
Next Page
507